Gliwice

• A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head … Recruiting
  2025-521917-24-00 5 2026-01-21 Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
• Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residua … Recruiting
  2024-512503-39-00 6 2025-12-19 Arm A (AML): Newly diagnosed de novo Acute myeloid leukemia (AML) or M
• A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants with Prostate Cancer Recruiting
  2024-517653-27-00 4 2025-12-17 Prostate Cancer
• A clinical study of MK-1084 and other treatments for lung cancer (MK-1084-007) Recruiting
  2024-514500-14-00 5 2025-12-15 Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
• A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep … Recruiting
  2024-513586-39-00 5 2025-12-10 Prostate Cancer
• A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg … Recruiting
  2025-523083-21-00 5 2025-12-08 PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
• A study to test whether treatment with BI 770371 in combination with pembrolizumab with or without cetuximab helps people with head and neck … Recruiting
  2024-517091-38-00 3 2025-11-25 Head and neck squamous cell carcinoma
• A trial to see if ficerafusp alfa given with pembrolizumab can treat participants with head and neck cancer. Recruiting
  2024-519654-37-00 10 2025-11-07 Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
• Phase IIIb Study of 36-Week Refill Exchanges of Port Delivery System with Ranibizumab in nAMD Recruiting
  2024-516924-32-00 5 2025-10-17 Neovascular Age-Related Macular Degeneration (nAMD)
• A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Descartes-08 in Patients With Generalized Myasthenia Gravis (MG) Recruiting
  2024-520355-25-00 5 2025-10-10 generalized myasthenia gravis
• A clinical study of MK-1084 with targeted therapy and chemotherapy in people with colorectal cancer (MK-1084-012). Recruiting
  2024-517232-22-00 5 2025-09-26 KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorect
• Study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients with Grade 1 and Grade 2 advanced GEP-NET (NETTER-3) Recruiting
  2024-518325-15-00 5 2025-09-08 Gastroenteropancreatic neuroendocrine tumor (GEP-NET)
• A Phase 1 Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases Recruiting
  2024-517681-41-00 1 2025-08-29 Systemic Sclerosis
• A clinical study of sacituzumab tirumotecan and pembrolizumab in people with endometrial cancer (MK-2870-033) Recruiting
  2024-519331-42-00 5 2025-08-22 pMMR endometrial carcinoma
• A Phase 2b Study to Assess the Efficacy and Safety of IMVT-1402 in Patients with Grave’s Disease Recruiting
  2024-516020-33-00 4 2025-06-26 Grave’s Disease
• Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting
  2024-515764-31-00 10 2025-06-13 Non-small cell lung cancer
• A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration ( … Recruiting
  2023-510294-34-00 5 2025-06-12 small lymphocytic lymphoma (SLL)
• A Phase I/II study of GSK5733584 in combination with anti-cancer therapies for advanced solid tumors Recruiting
  2024-517147-31-00 9 2025-05-23 Tumours, Gynecological
• A study in newly diagnosed glioblastoma patients that aims at testing the efficacy of Optune (Tumor Treating Fields), together with temozolo … Recruiting
  2024-513550-30-00 5 2025-03-28 Newly diagnosed Glioblastoma
• A clinical study of zilovertamab vedotin in people with large B-cell lymphoma (MK-2140-010) Recruiting
  2024-515566-13-00 5 2025-03-19 Diffuse Large B-Cell Lymphoma (DLBCL)
• Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Recruiting
  2024-513853-66-00 5 2025-02-04 KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colo
• A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer. Recruiting
  2023-510322-32-00 5 2025-01-27 patients with incurable, metastatic/recurrent head and neck squamous c
• A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of head and neck cancer Recruiting
  2023-510323-30-00 5 2025-01-24 First-line treatment of recurrent or metastatic PD-L1+ head and neck s
• Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc … Recruiting
  2024-513852-13-00 5 2025-01-20 KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Col

Showing 25–48 of 153 trials